Barry Ticho - May 1, 2023 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Chief Medical Officer
Signature
/s/ Stephen Tulipano, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
May 1, 2023
Transactions value $
-$555,267
Form type
4
Date filed
5/3/2023, 08:04 PM
Previous filing
Mar 17, 2023
Next filing
May 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Sale -$250K -25K -22.35% $10.00 86.8K May 1, 2023 Direct F1, F2
transaction STOK Common Stock Sale -$55.1K -5.51K -6.35% $10.00 81.2K May 2, 2023 Direct F1, F3
transaction STOK Common Stock Sale -$250K -24.7K -30.4% $10.14 56.5K May 3, 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.